Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bioventus Acquires Pfizer’s BMP Portfolio | Contract Pharma

What are you searching for?

Sign in
Breaking News

Bioventus Acquires Pfizer’s BMP Portfolio

Expands bone stimulation and injectable therapies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bioventus has entered an agreement with Pfizer for an exclusive, worldwide license to Pfizer’s bone morphogenetic protein (BMP) portfolio of development programs and associated assets. Pfizer received an upfront payment and will be eligible to receive milestone payments and royalties on sales. The portfolio includes a next-generation BMP and the rights to rhBMP-2 in indications and fields previously reserved to Pfizer. Bioventus has also acquired an exclusive option to a BMP program for soft tissue indications. 
 
Pfizer will transfer all existing development work for the BMP assets and undertake certain early-development activities relating to the next-generation BMP. Pfizer will also manufacture and supply rhBMP-2 to Bioventus.
 
“As Pfizer continues to prioritize and actively manage our dynamic pipeline, we have looked for strong partners who are best suited to advance programs outside our core focus areas,” said Jose Carlos Gutierrez-Ramos, Ph.D., group senior vice president and head of Biotherapeutics R&D at Pfizer. “Given Bioventus’ expertise and commitment to orthopedic healing, we believe it is well positioned to advance important new options to orthopedic patients.”
 
“This transaction strengthens our vision of Bioventus being a recognized global leader in active orthopedic healing. BMPs are a class of demonstrably potent biologics that will benefit from Bioventus’ commitment to developing clinically efficacious technologies in partnership with world-class physicians and the appropriate regulatory agencies. The BMP programs will expand and complement Bioventus’ ongoing development in bone stimulation and injectable hyaluronic acid therapies,” said Mark Augusti, chief executive officer of Bioventus.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics